Illumina, Inc. (ILU.DE) XETRA

Currency In EUR

AD

Illumina, Inc.

Address

5200 Illumina Way

San Diego, CA 92122

United States of America (the)

Phone

858 202 4500

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

8970

First IPO Date

October 15, 2007

Key Executives

NameTitlePayYear Born
Jacob ThaysenCEO, Interim Chief Commercial Officer & Director1.94M1975
Mark FieldChief Information Officer628,0171971
Kevin Carl PegelsChief of Global Operations760,0661968
Steven BarnardChief Technology Officer790,1801961
Ankur DhingraChief Financial Officer848,7271976
Patricia LeckmanSenior Vice President & Chief People Officer01964
Jakob WedelChief Strategy & Corporate Development Officer01972
Conor Noel McNamaraVice President of Investor Relations0N/A
Scott DaviesChief Legal Officer & Secretary01970
Stephanie CamposPresident0N/A
Scott EricksenVice President & Chief Accounting Officer01973
AD

Description

Established in 1998 and headquartered in San Diego, California, Illumina, Inc. delivers cutting-edge sequencing and array technologies crucial for genetic and genomic analysis. The company's comprehensive offerings empower clients across numerous sectors, facilitating the integration of genomic solutions into both research and clinical applications. These span critical fields such as life sciences, oncology, reproductive health, and agriculture. Illumina's product suite encompasses analytical instruments and their associated consumables, complemented by a range of services including genotyping, sequencing, instrument support contracts, development and licensing partnerships, and cancer detection testing. Its extensive customer base comprises genomic research centers, academic bodies, government laboratories, hospitals, pharmaceutical and biotechnology companies, commercial molecular diagnostic labs, and consumer genomics enterprises. The company directly distributes its products across North America, Europe, Latin America, and the Asia-Pacific region, while also leveraging life-science distributors to reach markets in Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

AD